BioCentury
ARTICLE | Clinical News

Bonti's EB-001A improves scar appearance following Mohs surgery in Phase IIa

August 10, 2018 6:10 AM UTC

Bonti Inc. (Newport Beach, Calif.) said EB-001A improved scar appearance by about 50% vs. placebo as measured by investigator-assessed visual analog scale (VAS) scores at day 30 in the Phase IIa SHINE-1 trial in 12 patients undergoing Mohs surgery. At 24 hours post-surgery, no patients in the EB-001A arm reported itching as measured by Scar Cosmesis Assessment and Rating (SCAR) scores vs. 75% of patients who received placebo. The company said EB-001A also improved pain scores and patient-reported scar color and stiffness vs. placebo.

Patients in the double-blind, U.S. trial received a single intramuscular injection of EB-001A into the forehead immediately following Mohs surgery...

BCIQ Company Profiles

Bonti Inc.